

September 9, 2021



MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference

NEW YORK, Sept. 9, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its Chief Medical Officer, Daniel R. Karlin, MD MA, will co-chair the 8th annual [Mobile in Clinical Trials Conference](#), which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.



MindMed

"I've always enjoyed co-chairing Mobile in Clinical Trials, together with my friend Michelle Shogren from Bayer," said Dr. Karlin. "We would have preferred a hybrid option allowing for in person interactions but the safety of attendees comes first. Last year's virtual format still enabled the fruitful exchange of the latest knowledge in the area of digital solutions, just as we had experienced during previous years of Mobile in Clinical Trials that took place in person."

The 8th annual Mobile in Clinical Trials Conference will feature the latest examples of deploying remote digital tools in clinical studies and will offer solutions for making digital technology an integral part of clinical research. Mobile in Clinical Trials is the event most attended by digital R&D operations leaders who are seeking solutions to apply mobile-digital tools into clinical research. Each year at this Conference, participants present experience-based case studies and exchange fresh ideas to advance fit-for-purpose adoption and scale-up of remote digital solutions in the area of clinical research.

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this news release include, but are not limited to, statements regarding MindMed's attendance at the Mobile in Clinical Trials Conference, Conference program and topics and Conference attendees. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings "Risk Factors" in the Company's filings with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Media Contact: mindmed@150bond.com

View original content to download multimedia: <https://www.prnewswire.com/news-releases/mindmed-to-attend-8th-annual-mobile-in-clinical-trials-conference-301372315.html>

SOURCE Mind Medicine (MindMed) Inc.